Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI.
Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of ...
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI.
Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C).
In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.
-
Number of Employees:
0-25
-
Annual Revenue:
$0-1 Million